Abstract
Radiation therapy (RT) can induce an immunogenic variant of regulated cell death that can initiate clinically relevant tumor-targeting immune responses. Immunogenic cell death (ICD) is accompanied by the exposure and release of damage-associated molecular patterns (DAMPs), chemokine release, and stimulation of type I interferon (IFN-I) responses. In recent years, intensive research has unraveled major mechanistic aspects of RT-induced ICD and has resulted in the identi-fication of immunogenic factors that are released by irradiated tumor cells. However, so far, only a limited number of studies have searched for potential biomarkers that can be used to predict if irradiated tumor cells undergo ICD that can elicit an effective immunogenic anti-tumor response. In this article, we summarize the available literature on potential biomarkers of RT-induced ICD that have been evaluated in cancer patients. Additionally, we discuss the clinical relevance of these findings and important aspects that should be considered in future studies.
Author supplied keywords
Cite
CITATION STYLE
Vaes, R. D. W., Hendriks, L. E. L., Vooijs, M., & De Ruysscher, D. (2021, April 1). Biomarkers of radiotherapy-induced immunogenic cell death. Cells. MDPI. https://doi.org/10.3390/cells10040930
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.